Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn’t
Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn’t Yahoo Finance
Covered in this story
What has happened since
- Pfizer is down 2.2% since this was published, 38 days ago.
- Starbucks is down 12.3% since this was published, 38 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Pfizer
- Scotiabank: $27.5 → $33 by Oct 2027 · Sector Outperform via GuruFocus
- BMO Capital Markets: $27.3 → $30 by Aug 2027 · Buy via 富途牛牛
- HSBC: $23.7 → $28 by Jul 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 49 stories mentioning Pfizer, the earliest published 18 Jun 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.